Arjan Diepstra
dr.
As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.
Latest publications
(216)
Activities
(38)
Press/Media
(7)
Prizes
(4)
Datasets
(1)
Supervised work
(12)
Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis
Published in: Blood
Access to document
10.1182/bloodadvances.2020003323
document
Erythrocytosis is a common reason for referral to hematology services and is usually secondary in origin. The aim of this study was to assess clinical characteristics and clonal hematopoiesis (CH) in individuals with erythrocytosis in the population-based Lifelines cohort (n 5 147 167). Erythrocytosis was defined using strict (World Health Organization [WHO] 2008/British Committee for Standards in Hematology) and wide (WHO 2016) criteria. Individuals with erythrocytosis (strict criteria) and concurrent leukocytosis and/or thrombocytosis were 1:2 matched with individuals with isolated erythrocytosis and analyzed for somatic mutations indicative of...
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial
Published in: Haematologica
Access to document
10.3324/haematol.2019.238162
document
Patients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients withoutMYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL. A phase II trial was conducted evaluating the efficacy of lenalidomide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in...
Martine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, Katerina Bakunina, Rogier Mous, Pieternella J Lugtenburg, Daan Dierickx, Gustaaf W van Imhoff, Joost S P Vermaat, Erik A F Marijt, Otto Visser, Caroline Mandigers, Yavuz M Bilgin, Aart Beeker, Mark F Durian, Bas van Rees, Lara H Bohmer, Lidwine W Tick, Rinske S Boersma, Tjeerd J F SnijdersHarry C Schouten, Harry R Koene, Eva de Jongh, Nathalie Hijmering, Arjan Diepstra, Anke van den Berg, Anne I J Arens, Julia Huijbregts, Otto Hoekstra, Josee M Zijlstra, Daphne de Jong, Marie José Kersten
Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58
Published in: Blood
Access to document
10.1182/blood.2020005546
document
A unique feature of Hodgkin lymphoma (HL) is the presence of CD4+ T cells that surround, protect, and promote survival of tumor cells. The adhesion molecules involved in this so-called T-cell rosetting are important components of the immunological synapse (IS). However, it is unknown whether this synapse is fully assembled and leads to T-cell activation by enabling interaction between the T-cell receptor (TCR) and human leukocyte antigen class II (HLA-II). We established a novel rosetting model by coculturing HLA-II-matched peripheral blood mononuclear cells with HL cell lines and...
Johanna Veldman, Lydia Visser, Magdalena Huberts-Kregel, Natasja Muller, Bouke Hepkema, Anke Van den Berg, Arjan Diepstra
Biopsy-Controlled Non-Invasive Quantification of Collagen Type VI in Kidney Transplant Recipients: A Post-Hoc Analysis of the MECANO Trial
Published in: Journal of Clinical Medicine
Access to document
10.3390/jcm9103216
document
The PRO-C6 assay, a reflection of collagen type VI synthesis, has been proposed as a non-invasive early biomarker of kidney fibrosis. We aimed to investigate cross-sectional and longitudinal associations between plasma and urine PRO-C6 and proven histological changes after kidney transplantation. The current study is a post-hoc analysis of 94 participants of the MECANO trial, a 24-month prospective, multicenter, open-label, randomized, controlled trial aimed at comparing everolimus-based vs. cyclosporine-based immunosuppression. PRO-C6 was measured in plasma and urine samples collected 6 and 24 months post-transplantation. Fibrosis was evaluated in...
Manuela Yepes-Calderón, Camilo G Sotomayor, Daniel Guldager Kring Rasmussen, Ryanne S Hijmans, Charlotte A Te Velde-Keyzer, Marco van Londen, Marja van Dijk, Arjan Diepstra, Stefan P Berger, Morten Asser Karsdal, Frederike J Bemelman, Johan W de Fijter, Jesper Kers, Sandrine Florquin, Federica Genovese, Stephan J L Bakker, Jan-Stephan Sanders, Jacob Van Den Born
F-18-FDG PET/CT in the Diagnostic and Treatment Evaluation of Pediatric Posttransplant Lymphoproliferative Disorders
Published in: Journal of Nuclear Medicine
Access to document
10.2967/jnumed.119.239624
document
We aimed to evaluate the diagnostic performance of 18F-FDG PET/CT for the detection of posttransplantation lymphoproliferative disorder (PTLD) in a pediatric population and explore its feasibility during response assessment. Methods: This retrospective study included 28 pediatric transplant recipients who underwent a total of 32 18F-FDG PET/CT scans due to clinical suspicion of PTLD within an 8-y period. Pathology reports and 2 y of follow-up were used as the reference standard. Twenty-one response assessment 18F-FDG PET/CT scans were reevaluated according to the Lugano criteria. Results: The diagnosis of PTLD...